查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1716301

2032 年退伍军人菌检测市场预测：按类型、样本类型、应用、最终用户和地区进行的全球分析

Legionella Testing Market Forecasts to 2032 - Global Analysis By Type (Culture Methods, Urine Antigen Testing, Polymerase Chain Reaction, Serology and Direct Fluorescent Antibody Test), Sample Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球退伍军人菌检测市场预计在 2025 年将达到 4.0163 亿美元，到 2032 年将达到 8.7136 亿美元，预测期内的复合年增长率为 11.7%。

退伍军人菌检测是检测水系统中退伍军人菌的存在的关键过程，有助于预防退伍退伍军人菌症（一种潜在的严重肺炎）。该测试通常在冷却塔、饭店、办公室和医院进行，以确保热水浴缸、管道系统和装饰喷泉等水源的安全。通常使用免疫学测定、聚合酵素链锁反应(PCR) 和培养技术来收集和分析水样本。此外，水安全管理计画应包括定期退伍军人菌检测，以支持公共卫生和法规遵循。

根据美国疾病管制与预防中心 (CDC) 的数据，2015 年至 2020 年间，美国报告的因水传播疾病爆发而住院的人数中，97% 是退伍军人菌引起的，死亡人数中，98% 是由美国菌引起的。

退伍军人菌病发生率上升

退伍退伍军人菌病的爆发不仅危险，而且还会给设施运营者带来严重的法律和经济后果。例如，2024年8月，澳洲维多利亚州记录了71例退伍军人菌病确诊病例和1例死亡病例，引起公众关注和监管审查的增加。退伍军人菌检测市场的主要驱动力是全球退伍军人菌病病例的增加，根据美国疾病管制与预防中心报告，2000 年至 2018 年间，美国报告的军团病病例数增加了五倍多。此外，日益加重的疾病负担迫使医疗机构、市政当局和建筑物业主实施积极的检测通讯协定，以检测并消灭供水系统中的退伍军人菌。

昂贵的先进测试技术

快速免疫检测、聚合酵素链锁反应(PCR) 和次世代定序(NGS) 等先进检测技术儘管速度快、准确，但价格昂贵。较小设施和发展中地区的发展通常受到专用设备、训练有素的人员和专有试剂成本的限制。预算限制迫使许多设施，特别是那些资源有限的设施，使用传统的培养方法，儘管这需要时间才能完成。此外，这种经济障碍可能会阻碍市场发展，特别是在卫生基础设施尚未发达且退伍军人菌尚未成为主要问题的地区。

结合智慧水资源管理系统

随着智慧建筑技术的日益普及，将退伍军人菌检测纳入更大的水质监测系统成为可能，智慧建筑技术可以自动控制水温、识别停滞情况并通知操作员有利于退伍军人菌生长的条件。结合自动或远端退伍军人菌检测，这些系统可以加快检测和合规速度，尤其是在较大的商业和工业设施中。此外，能够提供包括退伍军人菌检测在内的全面数位水资源管理解决方案的公司将在智慧建筑和设施管理市场领域占据有利地位，从而吸引资本。

缺乏基础设施和技术纯熟劳工

许多实验室和现场检测团队需要高技能的微生物学家和技术人员来执行先进的退伍军人菌诊断，例如 PCR 和培养确认。缺乏合格专业人员限制了服务的扩充性，尤其是在农村和开发中地区。此外，某些国家缺乏实验室处理、运输和水体采样的标准化基础设施，可能会导致结果不佳。技术能力的缺乏限制了发展并削弱了人们对退伍军人菌计画发展的信心。

COVID-19的影响：

COVID-19 疫情以多种方式影响了退伍军人菌检测市场。一方面，由于用水量减少而导致大面积建筑物关闭和封锁，管道系统中的积水增加了退伍军人菌生长的可能性。这导致人们的意识增强和检测需求激增，尤其是在准备安全重新开放的医院、住宿设施和商业建筑中。然而，尤其是在疫情初期，检测活动因供应链中断、场地访问受限和营运预算减少而暂时受到阻碍。但最终，这场危机凸显了定期环境监测的价值，退伍军人菌检测已成为后疫情时代设施管理和公共卫生的重要组成部分。

预计尿液抗原检测（UAT）领域将成为预测期内最大的领域。

预计预测期内尿液抗原检测（UAT）领域将占据最大的市场占有率。主要原因是该方法快速、易于使用且灵敏度高，特别是对于识别导致大多数退伍军人菌病病例的嗜肺性退伍军人桿菌1 血清群而言。 UAT 可以使用非侵入性尿液样本在数小时内提供结果，使其成为临床和医院环境中快速诊断和开始治疗的首选方法。此外，UAT 之所以能够在市场上领先于培养、PCR 和血清学等其他检测方法，关键因素在于其易于使用、被广泛接受以及能够在疫情调查期间促进广泛的筛检。

预计生物膜部分在预测期内将出现最高的复合年增长率。

预计生物膜部分将在预测期内见证最高的成长率。生物膜是退伍军人菌的长期家园，保护退伍军人菌免受恶劣环境和消毒剂的侵害。随着对生物膜在反覆污染中所扮演的角色的认识不断增加，对生物膜特定测试的需求也在增加。现在可以透过先进的采样和分子诊断技术更准确地检测出嵌入在系统组件和管道表面的细菌。此外，由于对生物膜测试的投资以及在冷却塔、医院和工业环境中越来越多地使用主动水安全管理计划，该领域的成长速度显着加快。

占比最大的地区：

由于先进诊断技术的广泛采用、广泛的认知度以及严格的法律规范，预计北美地区将在预测期内占据最大的市场占有率。尤其是在美国，疾病预防控制中心和职业安全与健康管理局等组织对水安全有严格的监督和规定，要求对商业建筑、老年护理院和医疗机构进行定期检测。完善的医疗保健基础设施、一流的诊断公司以及退伍军人菌的定期爆发凸显了积极检测的必要性。此外，由于强有力的公共卫生宣传活动和对感染控制的投资，北美目前是退伍军人菌检测的主要区域市场。

复合年增长率最高的地区：

在预测期内，由于工业基础设施的成长、快速的都市化以及对水传播感染疾病的认识的提高，预计亚太地区将呈现最高的复合年增长率。在中国、印度和东南亚等国家，医院、饭店和製造工厂的水安全变得越来越重要。政府努力提高公共卫生标准和国际诊断公司的扩张正在导致先进的退伍军人菌检测解决方案更广泛的应用。此外，由于环境卫生法规的加强和基础设施的老化，亚太市场预计将快速扩张，成为市场参与企业关注的重点地区。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章全球退伍军人菌检测市场（按类型）

  • 培养方法
  • 尿液抗原检测（UAT）
  • 聚合酵素链锁反应（PCR）
  • 血清学
  • 直接萤光抗体（DFA）检测

6. 全球退伍军人菌检测市场（依样本类型）

  • 水
  • 生物膜
  • 棉花棒样本

7. 全球退伍军人菌检测市场（按应用）

  • 水质检测
    • 微生物培养
    • DFA染色
    • PCR
  • 体外诊断（IVD）测试
    • 血液培养和痰液检查
    • 尿液抗原检测
    • DFA染色
    • PCR
  • 其他用途

8. 全球退伍军人菌检测市场（依最终用户）

  • 医院和诊所
  • 诊断实验室
  • 水处理业
  • 其他最终用户

9. 全球退伍军人菌检测市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Danaher Corporation
  • Quidel Corporation
  • Thermo Fisher Scientific, Inc.
  • Eurofins Scientific
  • IDEXX Corporation
  • Abbott Laboratories
  • Merck KGaA
  • Eiken Chemical Co., Ltd.
  • Aquacert Ltd.
  • Takara Bio, Inc.
  • LuminUltra Technologies Ltd.
  • Becton, Dickinson & Company
  • Pro-Lab Diagnostics, Inc.
  • Qiagen NV
  • Bio-Rad Laboratories, Inc.
Product Code: SMRC29112

According to Stratistics MRC, the Global Legionella Testing Market is accounted for $401.63 million in 2025 and is expected to reach $871.36 million by 2032 growing at a CAGR of 11.7% during the forecast period. Legionella testing is a critical process used to detect the presence of Legionella bacteria in water systems, helping to prevent Legionnaires' disease-a potentially severe form of pneumonia. Frequently carried out in cooling towers, hotels, offices, and hospitals, this testing guarantees the safety of water sources like hot tubs, plumbing systems, and ornamental fountains. Water sample collection and analysis usually entails the use of immunological assays, polymerase chain reaction (PCR), or culture techniques. Moreover, water safety management plans must include routine Legionella testing to support public health and regulatory compliance.

According to the Centers for Disease Control and Prevention (CDC), Legionella bacteria were responsible for 97% of hospitalizations and 98% of deaths resulting from reported waterborne disease outbreaks in the United States between 2015 and 2020.

Market Dynamics:

Driver:

Rising rate of legionnaires illness

Legionnaires' disease outbreaks are not only dangerous but can also have serious legal and financial ramifications for facility operators. For instance, in August 2024, Victoria, Australia, recorded 71 confirmed cases and one death from Legionnaires' disease, raising public concern and regulatory scrutiny. The primary driver of the Legionella testing market is the increasing number of Legionnaires disease cases worldwide, with the CDC reporting that reported cases of the disease more than fivefold increased in the United States between 2000 and 2018. Additionally, this increasing burden of disease is forcing healthcare facilities, municipalities, and building owners to implement proactive testing protocols to detect and eradicate Legionella bacteria from water systems.

Restraint:

Expensive advanced testing technologies

Advanced detection techniques such as rapid immunoassays, polymerase chain reaction (PCR), and next-generation sequencing (NGS) are expensive despite their speed and accuracy. Adoption in smaller facilities and developing regions is frequently constrained by the expense of specialized equipment, trained personnel, and proprietary reagents. Budgetary constraints force many facilities, particularly those with limited resources, to use traditional culture methods even though they take longer to complete. Furthermore, this financial obstacle has the potential to impede market expansion, especially in areas where health infrastructure is still being developed or where Legionella is not yet a major concern.

Opportunity:

Combining intelligent water management systems

Incorporating Legionella testing into larger water quality monitoring systems is made possible by the increasing use of smart building technology, which can automatically control water temperature, identify stagnation, and notify operators of conditions that are conducive to Legionella growth. When combined with automated or remote Legionella detection, these systems can expedite testing and compliance, especially in large commercial or industrial facilities. Moreover, businesses that can provide comprehensive digital water management solutions, including Legionella detection, are well-positioned to capitalize on the smart building and facility management market sectors.

Threat:

Absence of infrastructure and skilled workers

Highly skilled microbiologists or technicians are needed by many labs and field testing teams to carry out sophisticated Legionella diagnostics like PCR or culture confirmation. A lack of these qualified experts limits the scalability of services, particularly in rural or developing areas. Furthermore, in certain nations, the absence of standardized infrastructure for laboratory processing, transportation, and water sampling raises the possibility of subpar results. This lack of technical capability restricts development and undermines confidence in growing programs to control Legionella.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Legionella testing market. On the one hand, water stagnation in plumbing systems during lockdowns due to widespread building closures and decreased water usage raised the possibility of Legionella growth. This led to increased awareness and a spike in testing demand, especially in hospitals, lodging facilities, and business buildings getting ready for a safe reopening. However, particularly in the early phases of the pandemic, testing activities were momentarily hindered by supply chain disruptions, site access restrictions, and decreased operational budgets. But eventually, the crisis highlighted the value of regular environmental monitoring, making Legionella testing an essential part of facility management and public health in the post-pandemic world.

The urine antigen testing (UAT) segment is expected to be the largest during the forecast period

The urine antigen testing (UAT) segment is expected to account for the largest market share during the forecast period. The main reasons for its dominance are its speed, simplicity of use, and high sensitivity, especially when it comes to identifying Legionella pneumophila serogroup 1, which causes the majority of cases of Legionnaires' disease. Because UAT can provide results using non-invasive urine samples in a matter of hours, it is the method of choice for quick diagnosis and treatment initiation in clinical and hospital settings. Moreover, a major factor in its market dominance over other testing techniques like culture, PCR, or serology is its ease of use, broad acceptance, and capacity to facilitate extensive screening during outbreak investigations.

The biofilm segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biofilm segment is predicted to witness the highest growth rate. Biofilms act as a long-term home for Legionella bacteria, shielding them from harsh environments and disinfectants. There is an increasing need for biofilm-specific testing as knowledge of the part biofilms play in recurring contamination grows. Bacteria embedded in system components and pipe surfaces can now be detected with greater accuracy owing to advanced sampling and molecular diagnostics. Additionally, the segment is growing at a significantly faster rate owing to investments in biofilm testing and the growing use of proactive water safety management programs in cooling towers, hospitals, and industrial settings.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the high adoption of advanced diagnostic technologies, broad awareness, and strict regulatory frameworks. Particularly in the United States, strict surveillance and water safety regulations have been put in place by organizations like the CDC and OSHA, which require regular testing in commercial buildings, senior living facilities, and healthcare facilities. The necessity of proactive testing has been emphasized by the existence of a well-established healthcare infrastructure, top diagnostic firms, and regular Legionella outbreaks. Furthermore, North America is now the leading regional market for Legionella testing due to strong public health campaigns and investments in infection control.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by growing industrial infrastructure, fast urbanization, and growing awareness of waterborne illnesses. Water safety in hospitals, hotels, and manufacturing facilities is becoming increasingly important in countries like China, India, and Southeast Asia. Advanced Legionella testing solutions are becoming more widely used as a result of government initiatives to raise public health standards and the expansion of international diagnostic firms. Moreover, the Asia-Pacific market is expected to expand quickly as environmental health regulations tighten and infrastructure ages, making it a crucial area for industry participants to concentrate on.

Key players in the market

Some of the key players in Legionella Testing Market include Danaher Corporation, Quidel Corporation, Thermo Fisher Scientific, Inc., Eurofins Scientific, IDEXX Corporation, Abbott Laboratories, Merck KGaA, Eiken Chemical Co., Ltd., Aquacert Ltd., Takara Bio, Inc., LuminUltra Technologies Ltd., Becton, Dickinson & Company, Pro-Lab Diagnostics, Inc., Qiagen N.V. and Bio-Rad Laboratories, Inc.

Key Developments:

In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

In January 2025, Danaher Corporation announced that it has signed a definitive agreement to sell its Pacific Scientific Aerospace business to Meggitt PLC, a global aerospace and defense company. Danaher simultaneously received a binding offer from Meggitt to acquire the Artus business which remains open for 12 months.

In October 2024, Eurofins Scientific has reached an agreement with SYNLAB to acquire its clinical diagnostics operations in Spain. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. SYNLAB's clinical diagnostics operations in Spain provide clinical diagnostics testing, including genetics and anatomical pathology services, throughout the country, achieving revenues of approximately €140m in 2023.

Types Covered:

  • Culture Methods
  • Urine Antigen Testing (UAT)
  • Polymerase Chain Reaction (PCR)
  • Serology
  • Direct Fluorescent Antibody (DFA) Test

Sample Types Covered:

  • Water
  • Biofilm
  • Swab Samples

Applications Covered:

  • Water Testing
  • In Vitro Diagnostics (IVD) Testing
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Water Treatment Industries
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Legionella Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Culture Methods
  • 5.3 Urine Antigen Testing (UAT)
  • 5.4 Polymerase Chain Reaction (PCR)
  • 5.5 Serology
  • 5.6 Direct Fluorescent Antibody (DFA) Test

6 Global Legionella Testing Market, By Sample Type

  • 6.1 Introduction
  • 6.2 Water
  • 6.3 Biofilm
  • 6.4 Swab Samples

7 Global Legionella Testing Market, By Application

  • 7.1 Introduction
  • 7.2 Water Testing
    • 7.2.1 Microbial Culture
    • 7.2.2 DFA Stain
    • 7.2.3 PCR
  • 7.3 In Vitro Diagnostics (IVD) Testing
    • 7.3.1 Blood Culture and Sputum Tests
    • 7.3.2 Urinary Antigen Tests
    • 7.3.3 DFA Stain
    • 7.3.4 PCR
  • 7.4 Other Applications

8 Global Legionella Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Laboratories
  • 8.4 Water Treatment Industries
  • 8.5 Other End Users

9 Global Legionella Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Danaher Corporation
  • 11.2 Quidel Corporation
  • 11.3 Thermo Fisher Scientific, Inc.
  • 11.4 Eurofins Scientific
  • 11.5 IDEXX Corporation
  • 11.6 Abbott Laboratories
  • 11.7 Merck KGaA
  • 11.8 Eiken Chemical Co., Ltd.
  • 11.9 Aquacert Ltd.
  • 11.10 Takara Bio, Inc.
  • 11.11 LuminUltra Technologies Ltd.
  • 11.12 Becton, Dickinson & Company
  • 11.13 Pro-Lab Diagnostics, Inc.
  • 11.14 Qiagen N.V.
  • 11.15 Bio-Rad Laboratories, Inc.

List of Tables

  • Table 1 Global Legionella Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Legionella Testing Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Legionella Testing Market Outlook, By Culture Methods (2024-2032) ($MN)
  • Table 4 Global Legionella Testing Market Outlook, By Urine Antigen Testing (UAT) (2024-2032) ($MN)
  • Table 5 Global Legionella Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 6 Global Legionella Testing Market Outlook, By Serology (2024-2032) ($MN)
  • Table 7 Global Legionella Testing Market Outlook, By Direct Fluorescent Antibody (DFA) Test (2024-2032) ($MN)
  • Table 8 Global Legionella Testing Market Outlook, By Sample Type (2024-2032) ($MN)
  • Table 9 Global Legionella Testing Market Outlook, By Water (2024-2032) ($MN)
  • Table 10 Global Legionella Testing Market Outlook, By Biofilm (2024-2032) ($MN)
  • Table 11 Global Legionella Testing Market Outlook, By Swab Samples (2024-2032) ($MN)
  • Table 12 Global Legionella Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 13 Global Legionella Testing Market Outlook, By Water Testing (2024-2032) ($MN)
  • Table 14 Global Legionella Testing Market Outlook, By Microbial Culture (2024-2032) ($MN)
  • Table 15 Global Legionella Testing Market Outlook, By DFA Stain (2024-2032) ($MN)
  • Table 16 Global Legionella Testing Market Outlook, By PCR (2024-2032) ($MN)
  • Table 17 Global Legionella Testing Market Outlook, By In Vitro Diagnostics (IVD) Testing (2024-2032) ($MN)
  • Table 18 Global Legionella Testing Market Outlook, By Blood Culture and Sputum Tests (2024-2032) ($MN)
  • Table 19 Global Legionella Testing Market Outlook, By Urinary Antigen Tests (2024-2032) ($MN)
  • Table 20 Global Legionella Testing Market Outlook, By DFA Stain (2024-2032) ($MN)
  • Table 21 Global Legionella Testing Market Outlook, By PCR (2024-2032) ($MN)
  • Table 22 Global Legionella Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 23 Global Legionella Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 24 Global Legionella Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 25 Global Legionella Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 26 Global Legionella Testing Market Outlook, By Water Treatment Industries (2024-2032) ($MN)
  • Table 27 Global Legionella Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.